Highlight Therapeutics announces completion of enrollment for Phase 2b study of BO-112 in large, underserved basal cell ...

The FDA has accepted a sNDA for Ameluz topical gel, used in combination with the RhodoLED red-light lamp series, for superficial basal cell carcinoma treatment.

Teddi Mellencamp reflected her cancer journey one year after being diagnosed with the disease, admitting to feeling “a lot of ...

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first ...

The FDA accepted the supplemental new drug application (sNDA) for aminolevulinic acid hydrochloride 10% topical gel (Ameluz) as part of photodynamic therapy (PDT) for superficial basal cell carcinoma ...

US FDA acknowledges no filing deficiencies in Biofrontera’s sNDA for Ameluz PDT in superficial basal cell carcinoma: Woburn, Massachusetts Saturday, February 14, 2026, 16:00 Hrs ...

A study has examined whether there is a link between skin cancer found on the right side of the face and the side of the road ...

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal ...

The most detailed atlas of tumour cells from the deadliest form of pancreatic cancer has been developed by an global team of researchers ...

Merkel cell carcinoma is a rare and aggressive form of neuroendocrine skin cancer. While it accounts for a small fraction of ...